BALAXI PHARMACEUTICALS LIMITED

Ashish Maheshwari

— CHAIRMAN & MANAGING

rs,

as a couple of warehouses and have delivery vans to supply goods under this vehicle, to distributors, supermarkets, and general stores. We sell Biscuits under our own brand name “YAP.” We also launche

Rs.178 crore

ts, Hand Sanitizers, etc., Coming to the “Financial Performance’, the company recorded revenue of Rs.178 crores in nine months ended December 2020. EBITDA came in at Rs.30.9 crores. EBITDA margin was 17.3%.

Rs.30.9 crore

e company recorded revenue of Rs.178 crores in nine months ended December 2020. EBITDA came in at Rs.30.9 crores. EBITDA margin was 17.3%. And the profit aftera tax was Rs.29.8 crores. PAT margin stands at aro

17.3%

78 crores in nine months ended December 2020. EBITDA came in at Rs.30.9 crores. EBITDA margin was 17.3%. And the profit aftera tax was Rs.29.8 crores. PAT margin stands at around 16.7%. “Segmental Pe

Rs.29.8 crore

er 2020. EBITDA came in at Rs.30.9 crores. EBITDA margin was 17.3%. And the profit aftera tax was Rs.29.8 crores. PAT margin stands at around 16.7%. “Segmental Performance.” Revenue from pharmaceuticals busine

16.7%

BITDA margin was 17.3%. And the profit aftera tax was Rs.29.8 crores. PAT margin stands at around 16.7%. “Segmental Performance.” Revenue from pharmaceuticals business stood at Rs.105 crores for the

Rs.105 crore

n stands at around 16.7%. “Segmental Performance.” Revenue from pharmaceuticals business stood at Rs.105 crores for the nine months of FY’21. Sales mix of branded generics for Q3 FY’21 was 28:72; 28% was br

28%

Rs.105 crores for the nine months of FY’21. Sales mix of branded generics for Q3 FY’21 was 28:72; 28% was branded and generics was 72% which is a slight improvement because overall Hl FY’21 was 24:

72%

of FY’21. Sales mix of branded generics for Q3 FY’21 was 28:72; 28% was branded and generics was 72% which is a slight improvement because overall Hl FY’21 was 24:76. We are focused on growing our

59%

anded generics share of our overall pharma sales. The pharmaceuticals business contributes around 59% of total revenue and 68% of our total EBITDA. Our branded consumer products business rebounded af

68%

ur overall pharma sales. The pharmaceuticals business contributes around 59% of total revenue and 68% of our total EBITDA. Our branded consumer products business rebounded after COVID impacted Q2 of

114%

r products business rebounded after COVID impacted Q2 of FY’21. This segment reported increase of 114% quarter-on-quarter in revenue and 175% quarter-on-quarter growth in profit after taxes. We have a

“We aim to further strengthen our market share in the existing geographies of Angola, Guatemala and Dominican Republic and poised to expand in Honduras, E] Salvador, Nicaragua and Central African Republic.”

“And we plan to add other products like Disinfectants, Hand Sanitizers, etc., Coming to the “Financial Performance’, the company recorded revenue of Rs.178 crores in nine months ended December 2020.”

“Balaxi is well positioned to capture incremental market share in existing geographies and expanding into other target territories.”

“One product we're going to launch in this financial year is Tomato Ketchup and Mayonnaise which will be in addition to our FMCG basket what we already have.”

“Going forward, our total concentration is only on pharmaceuticals.”

“Now we do not have these businesses in Dominican Republic or Guatemala, neither are we trying plan to do this business in other geographies of E] Salvador, Honduras, Nicaragua, or Central African Republic.”

“And the ancillary hardware business has saturated already in Angola more or less, but sometimes we see spikes of 10%, 20% but on overall financial year level it is a bit saturated, we won't have much place to grow there, it will grow at a normal percentage.”

“From Central America, the total growth will be from pharma only.”

“As the product registrations are constant currently at 548, so when do you expect it to increase, I mean, by number if you can tell me the exact number by the end of FY’21?”

“In fact in this Q4, we are expecting at least 40 product registrations to come up in this quarter and more in the next quarter.”

Ashish Maheshwari

32

Agastya Dave

11

Sachin Shetty

10

Moderator

9

Devendra Pandey

6

Ashok Agrawal

2

MODERATOR

1

Aakash Mehta

1

Aditi Sawant

1

Aakash Mehta

Thank you. Good evening, everyone. I welcome you all to the Q3 & Nine Months FY’21 Earnings Call of Balaxi Pharmaceuticals Limited. We have with us Mr. Ashish Maheshwari, the Chairman and Managing Director from the company. The discussion today may include some forward-looking statements and must be reviewed or considered in conjunction with the risk in the industry in general and our business. Now I hand over the call to Mr. Ashish Maheshwari for his opening remark. Over to you sir.

Ashish Maheshwari

Good evening, everyone. On behalf of Balaxi Pharmaceuticals, I extend a warm welcome to everyone to this earnings conference call for discussing overall performance in the quarter and the nine months ended 31st December ’20. This is our maiden earnings call and hence marks a special beginning for us. We have issued a detailed “Press Release”, “Investor Presentation” for the quarter. Hopefully all of you had a chance to review it. At the outset I hope that all your loved ones are healthy and doing well in these unprecedented times. I would first like to give a brief overview of the company, followed by the review on the financial performance during the quarter and the nine months ended 31“ December ’20. After this, we shall take questions from the participants. Balaxi Pharmaceuticals Limited is a branded IPR-based pharmaceutical player, focusing on frontier markets with a fast and growing portfolio of prescription and OTC drugs across multiple therapeutic segments. The company is engage